Q: What types of documents does a regulatory medical writing service produce?
A: Regulatory medical writing encompasses a broad range of submission-critical documents: Common Technical Documents (CTD) including Module 2 overviews and summaries; Clinical Study Reports (CSRs) per ICH E3; Investigational New Drug (IND) and New Drug Application (NDA/BLA) components; Marketing Authorization Application (MAA) modules for EMA submissions; Periodic Safety Update Reports (PSURs) and PBRERs; Risk Management Plans (RMPs); Summary of Product Characteristics (SmPC) and Patient Information Leaflets (PILs); REMS documents; regulatory responses to health authority queries; and Clinical Evaluation Reports (CERs) for medical devices.
Q: What is a CTD and what does Module 2 contain?
A: The Common Technical Document (CTD) is the internationally harmonized regulatory submission format used across ICH regions (EU, USA, Japan, Canada, etc.). It comprises five modules. Module 2 — prepared by regulatory medical writers — contains the critical synthesized summaries: the Quality Overall Summary (QOS/Module 2.3), Nonclinical Overview (2.4) and Summaries (2.6), and Clinical Overview (2.5) and Summary (2.7). These documents must accurately integrate and interpret data from Modules 3 (quality), 4 (nonclinical), and 5 (clinical), and are the first documents reviewers read.
Q: What distinguishes a high-quality regulatory medical writer from a general scientific writer?
A: Regulatory medical writers possess specialized expertise beyond scientific communication: deep knowledge of ICH guidelines (E3, E6, M4, E2C), regional regulatory requirements (EU SmPC guideline, FDA 21 CFR Part 201 labeling), eCTD formatting requirements (ICH M8), and the ability to integrate large, complex datasets into coherent authority-ready narratives. They understand regulatory strategy, work cross-functionally with regulatory affairs, clinical, biostatistics, and safety teams, and must produce documents that are both scientifically accurate and strategically positioned for regulatory success.
Q: What is a Clinical Study Report (CSR) and what ICH guideline governs it?
A: A CSR is a comprehensive integrated report of an individual clinical study combining the clinical and statistical description, presentations, and analyses of the study in a single document. It is governed by ICH E3 (Structure and Content of Clinical Study Reports). CSRs are core components of NDA/BLA and MAA submissions and must include: study synopsis, background, objectives, methods, results, safety data, statistical analyses, and appendices with patient data listings. High-quality CSRs accurately reflect the statistical analysis plan and protocol, with discrepancies clearly explained.
Q: What is a Risk Management Plan (RMP) and when is it required?
A: An RMP is a detailed document accompanying an EU Marketing Authorization Application that describes the risk profile of a medicinal product, how significant risks will be characterized and minimized, and the plan for studying identified and potential risks. It is required for all new MA applications to the EMA and for certain post-approval changes. The RMP includes: safety specification; pharmacovigilance plan; risk minimization measures (routine and additional, such as aRMMs); and PSUR/PBRER update commitments. The RMP must be updated whenever new risk information becomes available.
Q: What is the difference between a SmPC and a USPI (US Prescribing Information)?
A: Both documents provide essential clinical information for healthcare professionals, but their formats and content requirements differ substantially. The EU SmPC follows the EMA’s QRD template (31 mandatory sections covering product name, composition, indications, dosage, contraindications, warnings, pharmacology, etc.) and accompanies the PIL. The US USPI follows the FDA Physician Labeling Rule (PLR) format under 21 CFR Parts 201 and 314 — requiring Highlights, Full Prescribing Information (including Boxed Warning if applicable), and Patient Counseling Information. Labeling strategy must account for both formats in global development programs.
Comments are closed